Mineralys Therapeutics Inc MLYS

$21.58 +0.66 (3.15%)

Valuation

Market cap
1,849,474,000
Revenue TTM
$0
Net income TTM
$-154,650,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.18

Trading

Volume
1,000,900
Avg volume
1,269,582
Day's range
$20.58 – $21.76
Shares out
88,407,000
Stochastic %K
41%
Beta
0.69
Analysts
Strong Sell
Price target
$46.33

Price

Company profile

Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep a...

Show more

Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Industry
Biotechnology
Sector
Healthcare
Phone
888 378 6240
Website
https://mineralystx.com
Address
150 N. Radnor Chester Road, Suite F200, Radnor, United States

Latest news

Stocktwits

CH_Expat Oct 20, 7:30 PM
$MLYS If you know what I mean.
0 replies
StockBen4444 Oct 20, 6:44 PM
$MLYS i think this will have a potential run up until november 8th for the long term study. Then it will decide wether it goes up until december decision. This is just my sight of this story!
1 replies
Valueforall Oct 20, 1:59 PM
$MLYS nice little boner& action today. Would like $22+ to feel like we are out of the graveyard 🪦
1 replies
CH_Expat Oct 20, 8:13 AM
$MLYS Two new board members at MLYS with plenty of M&A experience on the selling and buying side.
1 replies
Merlintrader Oct 17, 5:13 PM
📅 CATALYST REMINDER | $MLYS October 21–25, 2026 (conference window) — Clinical Data Presentation An analysis of lorundrostat Launch-HTN data on blood pressure and albuminuria in chronic kidney disease is scheduled during ASN Kidney Week. The individual session day is not specified. More details in our hub. #MLYS #Biotech #KidneyWeek
0 replies
Blind_Trader_ Oct 16, 6:03 PM
$MLYS never try to catch a falling knife
2 replies
StockBen4444 Oct 16, 5:53 PM
$MLYS is this real? Can‘t believe that is slipping away like this.
0 replies
roscoe44 Oct 16, 5:19 PM
$MLYS Brutal, This one is weak every day for past month.
1 replies